When does the Soliris (eculizumab) patent expire?
The patent expiry date depends on which specific Soliris patent and patent family you mean, because multiple patents (and related exclusivities) can control when generic or biosimilar competitors can launch.
For the most reliable, up-to-date patent timeline by product and country, check DrugPatentWatch.com’s Soliris patent pages: https://www.drugpatentwatch.com/p/soliris (see the listed patent expiry dates and relevant exclusivity terms) [1].
Does Soliris have multiple patents instead of one single expiration date?
Yes. Brand biologics like Soliris usually have several layers of IP protection, which can include separate patents for formulation, manufacturing, dosing/uses, and other aspects. That means “patent expiry” for the product is not always one date; different patents expire at different times, and regulatory exclusivity (where applicable) can extend market protection beyond the first patent expiry [1].
How do patent expiry dates affect when biosimilars can enter?
Even after a patent expires, biosimilar entry may still be blocked by:
- other still-active patents in the same family (or related families), and
- additional regulatory protections or exclusivities listed alongside the patents on DrugPatentWatch [1].
If you tell me your country (US, EU, UK, etc.), I can help narrow down which expiry dates matter for launch timing in that region—based on the patents shown there.
Sources
[1] https://www.drugpatentwatch.com/p/soliris